Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 17, 2025, titled "Zydus Lifesciences Limited announces the execution of undertakings to tender as part of its envisaged tender offer for Amplitude Surgical SA shares".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty 100 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zydus Lifesciences has shared a press release confirming it has executed undertakings to tender shares as part of its planned tender offer for Amplitude Surgical SA, a surgical devices company listed on Euronext Paris. This indicates that shareholders holding Amplitude Surgical shares have formally committed to tendering their holdings to Zydus as part of the offer process. The tender offer is described as 'envisaged,' meaning the broader acquisition process is still progressing toward completion. No final acceptance ratio, deal value, or timeline for closing has been disclosed in this filing.
This is a positive incremental step toward Zydus completing its acquisition of Amplitude Surgical SA and expanding its surgical devices footprint internationally. Shareholders should watch for further updates on the tender offer's completion, acceptance levels, and any open offer or regulatory steps that may follow in France.